Literature DB >> 19410324

Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.

Gerda Rudolph1, Daniel Gotthardt, Petra Klöters-Plachky, Hasan Kulaksiz, Daniel Rost, Adolf Stiehl.   

Abstract

BACKGROUND/AIMS: In primary sclerosing cholangitis (PSC) dominant stenoses are frequently associated with bacterial, and in part, also fungal infections of the bile ducts. In the present study, the influence of dominant stenoses and of biliary infections on the long-term outcome was studied.
METHODS: In a prospective study, 171 patients were followed up for 20 years. All patients were treated with ursodeoxycholic acid. Dominant stenoses were treated endoscopically and during endoscopic procedures, bile was obtained for microbiologic analysis.
RESULTS: Of the 171 patients, 97 had or developed major bile duct stenoses and 96/97 were treated endoscopically. In the 55/97 patients with dominant stenosis, bile samples were obtained and of these, 41/55 had bacteria, five had also Candida and 2/55 had only Candida in their bile. Survival free of liver transplantation in patients without dominant stenosis at 18 years was 73.1% and of patients with dominant stenosis was 25.0% (p=0.011). Bacteria in bile had no effect on survival whereas Candida in bile was associated with reduced survival (p=0.025).
CONCLUSIONS: In patients with dominant stenosis, survival free of liver transplantation is reduced. Bacteria in bile do not worsen the outcome if dominant stenoses are opened endoscopically and infection is adequately treated with antibiotics. Candida in bile is associated with a poor prognosis and these patients need liver transplantation relatively soon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410324     DOI: 10.1016/j.jhep.2009.01.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

1.  High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

Authors:  M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2011-09-29       Impact factor: 8.171

2.  Primary sclerosing cholangitis: The importance of treating stenoses and infections.

Authors:  Jens J W Tischendorf; Ramin Schirin-Sokhan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12       Impact factor: 46.802

3.  Management of primary sclerosing cholangitis.

Authors:  Holger H Lutz; Jens Jw Tischendorf
Journal:  World J Hepatol       Date:  2011-06-27

Review 4.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

Review 5.  Primary sclerosing cholangitis: diagnosis and treatment.

Authors:  Holger Lutz; Christian Trautwein; Jens W Tischendorf
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

Review 6.  Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist.

Authors:  Kunjam Modha; Udayakumar Navaneethan
Journal:  World J Hepatol       Date:  2015-04-18

Review 7.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

8.  Association of diverse bacterial communities in human bile samples with biliary tract disorders: a survey using culture and polymerase chain reaction-denaturing gradient gel electrophoresis methods.

Authors:  E Tajeddin; S J Sherafat; M R S Majidi; M Alebouyeh; A H M Alizadeh; M R Zali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-18       Impact factor: 3.267

Review 9.  Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Authors:  Souvik Sarkar; Christopher L Bowlus
Journal:  Clin Liver Dis       Date:  2015-10-06       Impact factor: 6.126

Review 10.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.